David Ayelet, Stolar Orit, Berkovitch Matitiahu, Kohn Elkana, Waisman-Nitzan Michal, Hartmann Inbar, Gal Eynat
Department of Occupational Therapy, Faculty of Social Welfare and Health Sciences, University of Haifa, Haifa, Israel.
Child Development Centers, Sharon District-Maccabi HealthCare Services, Ramat Hasharon, Israel.
Med Cannabis Cannabinoids. 2024 Apr 16;7(1):68-79. doi: 10.1159/000538901. eCollection 2024 Jan-Dec.
Medical cannabis treatment for autistic children has recently become popular, and studies have focused on examining the treatment's effects on children's symptom presentation, reported side effects, and dropout rates. However, no previous study has investigated the factors influencing adherence and dropout rates in cannabis treatment.
This explanatory sequential mixed-methods study explored these factors by examining the characteristics of 87 autistic children and their families and deepening parents' perspectives and experiences of the 6-month CBD-rich cannabis treatment's benefits and barriers.
We found this treatment to have a high (75%) adherence rate, relatively mild side effects, and substantial reported benefits for the children and families. However, this treatment was not free of barriers; the intake regime, some side effects, and in some cases, unrealistic parental expectations made adherence difficult for some families.
Our results highlight the importance of providing professional guidance and knowledge to parents of autistic children, enhancing their understanding of the impact of CBD-rich cannabis treatment on their children and expected related challenges, and coordinating realistic treatment expectations. We hope that addressing these important aspects will influence parents' ability to adhere to and enjoy the benefits of cannabis treatment for their autistic children.
医用大麻治疗自闭症儿童最近变得流行起来,研究主要集中在考察该治疗对儿童症状表现、报告的副作用及退出率的影响。然而,此前尚无研究调查影响大麻治疗依从性和退出率的因素。
这项解释性序列混合方法研究通过考察87名自闭症儿童及其家庭的特征,并深入了解父母对为期6个月的富含大麻二酚的大麻治疗的益处和障碍的看法及经历,来探究这些因素。
我们发现这种治疗的依从率很高(75%),副作用相对较轻,且儿童及其家庭报告有诸多益处。然而,这种治疗并非没有障碍;服用方案、一些副作用,以及在某些情况下不切实际的父母期望,使得一些家庭难以坚持治疗。
我们的研究结果凸显了向自闭症儿童家长提供专业指导和知识的重要性,增强他们对富含大麻二酚的大麻治疗对其子女的影响以及预期相关挑战的理解,并协调现实的治疗期望。我们希望解决这些重要方面将影响家长坚持让自闭症子女接受大麻治疗并从中受益的能力。